Could a change in diet to boost the immune system be helpful for treating cystic fibrosis? Researchers from the Czech Republic are betting on that possibility, and are currently enrolling volunteers for a clinical trial. Cystic fibrosis is one of the most commonly occurring chronic diseases of the lungs in…
Researchers at The University of British Columbia (UBC) recently opened a clinical trial designed to assess the sensation of shortness of breath or dyspnea in patients with cystic fibrosis (CF) during exercise. The study, titled “Qualitative Descriptors of Dyspnea During Exercise in Cystic Fibrosis”…
A study published in the journal Alcoholism: Clinical and Experimental Research revealed that the heavy drinking habits of lung donors can influence the outcome of lung transplantation in recipient patients. The study is entitled “Heavy Alcohol Use in Lung Donors…
Proteostasis Therapeutics, Inc. (PTI), a biotechnology company focused on discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis, has just revealed a novel class of therapeutics called, CFTR Amplifiers, indicated for cystic fibrosis (CF). These agents work to enhance…
A new review on the impact of the microbiome in the upper airways on URTIs entitled, “The microbiome of the upper airways: focus on chronic rhino sinusitis” was recently published in the World Allergy Organization Journal by Thanit Chalermwatanachai, part of Dr. Claus…
My little sister, Jennifer, was a beautiful woman who, like myself, fought Cystic Fibrosis throughout her life and on Saturday, February 7, she passed away at twenty-three after her body rejected the set of lungs she had received by transplantation the previous October in Denver, Colorado. Cystic Fibrosis, like other…
Arkansas Medicaid has settled a federal lawsuit brought by three cystic fibrosis (CF) patients who were denied the CF drug Kalydeco because of its high cost, according to a report by the Wall Street Journal‘s Joseph Walker. Kalydeco (generic name Ivacaftor) is an orally administered drug engineered…
Celtaxsys, Inc., a privately-owned, clinical stage drug discovery and development company focused on addressing serious inflammatory diseases, has just announced the U.S. Food and Drug Administration has granted the company’s experimental therapy CTX-4430 (oral leukotriene A4 hydrolase inhibitor) Orphan Drug Designation as a potential treatment…
Norwood, Massachusetts-based Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company specializing in the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory-fibrotic diseases, has just announced it has been invited to present at this week’s 17th Annual BIO CEO & Investor Conference. The conference, which will take place from February 9 to…
UK-based non-profit organization, Cystic Fibrosis Trust, recently launched a new awareness campaign that seeks to empower individuals living with cystic fibrosis (CF) to find out which specific CFTR gene mutation they are carrying. When patients know their specific mutation, physicians can prescribe more targeted, effective treatments, and even help patients participate in appropriate clinical…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.